About Edesa Biotech
Edesa Biotech is a publicly listed company based in Toronto (Canada) founded in 2015 by Par Nijhawan. It operates as a topical therapeutics for dermatological and gastrointestinal diseases are developed. The company has 16 employees. Its chief executive is Par Nijhawan. Edesa Biotech offers products and services including Monoclonal Antibodies and Host Directed Therapeutics. Its focus areas include Life Sciences, Dermatology, Drugs and Diversified. Its legal entity is STELLAR BIOTECHNOLOGIES, INC. Its competitors include LEO Pharma, Incyte, Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Edesa Biotech was founded in 2015 and is based in Toronto, Canada. Focus is placed on the biotechnology sector, where topical therapeutics for dermatological and gastrointestinal conditions are developed. Specific targets include contact dermatitis, hemorrhoids, and anal fissures. The lead product, EB-01, is advanced to Phase II trials for allergic contact dermatitis. Phase I candidates consist of EB-05 for irritant contact dermatitis, EB-02 for hemorrhoids, and EB-04 for anal fissures.
- Headquarters Toronto, Canada
- Employees 16
- Founders Par Nijhawan
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website edesabiotech.com
- Social LinkedIn X
- Legal Name Edesa Biotech, Inc.
- Net Profit-$7.19 M (USD)-16.46as on Sep 30, 2025
- EBITDA-$7.79 M (USD)-14.11as on Sep 30, 2025
- Latest Funding Round$3.5M (USD), Post-IPO
Jun 2026
- InvestorsPharmaScience
& 8 more
- Employee Count16
Products & Services of Edesa Biotech
Edesa Biotech offers a comprehensive portfolio of products and services, including Monoclonal Antibodies and Host Directed Therapeutics.
Antibodies targeting immune dysregulation in inflammatory diseases
Treatments modulating pathways for multiple immune-related conditions
Funding Insights of Edesa Biotech
- Total Rounds 5
- Last Round Post-IPO — $3.5M
- First Round $7M
(Sep 2017)
- Investors Count 9
All 5 funding rounds of Edesa Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $3.5M | Post-IPO | – | – | – |
| Feb 2025 | $15M | Post-IPO | – | Velan Capital | |
| Nov 2022 | $3M | Post-IPO | – | – | – |
| Feb 2021 | – | Grant | – | – | |
| Sep 2017 | $7M | Post-IPO | – | Lumira Ventures |
9 investors in total: 9 institutional.
Investors in Edesa Biotech
Edesa Biotech has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include PharmaScience, Canadian Space Agency and Velan Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | velancapital.com | - | |
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
Lumira Ventures is engaged in life sciences venture capital investment. | – | lumiraventures.com | Toronto, Canada | |
Inveready is recognized as a leading Spanish financial services firm. | 2008 | inveready.com | San Sebastián, Spain | |
Fundamentally-driven firm investing in micro-cap stocks with long and short strategies. | 2004 | nantahalapartners.com | New Canaan, United States | |
Investment management services are offered by Rubric Capital. | – | rubriccapital.com | New York, United States | |
Life-science investment management firm providing advisory and capital services in biotechnology and healthcare. | 2006 | stonepinecap.com | Bend, United States | |
Canadian space agency focused on social and economic benefits | 1989 | asc-csa.gc.ca | Longueuil, Canada | |
Generic, branded, and over-the-counter pharmaceuticals are manufactured for global markets. | 1983 | pharmascience.com | Montreal, Canada |
Investor details for Edesa Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Edesa Biotech
10 people are tracked at Edesa Biotech (7 in leadership, 3 in team); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Par Nijhawan | Founder & CEO | Leadership |
Gary K. | Vice President, Corporate Affairs | Leadership |
Larissa Costa, Ph.D. | Associate Director, CMC | Leadership |
Blair Gordon | Vice President Research And Development | Leadership |
Nishani R. | Director Of Clinical Operations | Leadership |
Leo Bonifacio | Director Of Business Development | Leadership |
Irene F. | Director Of Regulatory Affairs | Leadership |
Karina Tamy Kasawara | Research and Development Associate | Team |
Daniella Afonso | Manager Of Research And Development | Team |
Kainat Amir | Clinical Operations Manager | Team |
Complete people profiles for Edesa Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Edesa Biotech
Edesa Biotech is a publicly listed company on the NASDAQ with ticker symbol EDSA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jun 2010
- Listed onNASDAQ: EDSA
- Listed entityEdesa Biotech, Inc.
- Exchange sectorHealth technology
- ISINCA27966L3065
- Share price$2.85 (-3.23% on the day) · 2026-10-13
- Market capitalisation$38.4M
- EPS (diluted, trailing year)$-1.69
- Volume (last session)61,373
Financials of Edesa Biotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$7.2M | -$7.8M |
| 2024 | – | -$6.2M | -$6.8M |
| 2023 | – | -$8.4M | -$9.0M |
| 2022 | – | -$17.6M | -$18.2M |
| 2021 | – | -$13.3M | -$23.6M |
Detailed financial statements for Edesa Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Edesa Biotech
4 dated milestones of Edesa Biotech across 16 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Founded Edesa Biotech is founded.
- Funding First funding round of $7.0M.
- Funding Latest funding round, Post-IPO, of $3.5M.
Competitors of Edesa Biotech
Edesa Biotech has 9 listed competitors in our database, 8 of them funded. They include LEO Pharma, Incyte, Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| leo-pharma.com | 1908 | Copenhagen, Denmark | $560.38M | 142 | Developer of drugs for treating dermatology diseases | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| formation.bio | 2016 | New York, United States | $608.25M | – | AI-powered drug discovery platform for various diseases | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. |
Detailed competitors of Edesa Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Edesa Biotech
The website of Edesa Biotech (edesabiotech.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 24.8% vs previous month
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Edesa Biotech (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Edesa Biotech
Complete news archive for Edesa Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Edesa Biotech
Edesa Biotech was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Edesa Biotech is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Par Nijhawan is the current CEO of Edesa Biotech. They have also founded this company.
Edesa Biotech has 16 employees.
Edesa Biotech was founded in 2015 and is based in Toronto, Canada. Focus is placed on the biotechnology sector, where topical therapeutics for dermatological and gastrointestinal conditions are developed. Specific targets include contact dermatitis, hemorrhoids, and anal fissures. The lead product, EB-01, is advanced to Phase II trials for allergic contact dermatitis. Phase I candidates consist of EB-05 for irritant contact dermatitis, EB-02 for hemorrhoids, and EB-04 for anal fissures.
Edesa Biotech's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and LEO Pharma.
Edesa Biotech offers Monoclonal Antibodies and Host Directed Therapeutics.
Yes, Edesa Biotech is publicly traded on NASDAQ under the ticker symbol EDSA.
Edesa Biotech has 9 investors. Key investors include PharmaScience, Canadian Space Agency, Velan Capital, Nantahala Capital Management, and Rubric Capital.
Edesa Biotech operates through Stellar Biotechnologies, Inc..